Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Memorial Sloan Kettering Cancer Center showed that a small group of chronic lymphocytic leukemia patients experienced treatment-resistant mutations in a clinical trial for Loxo-305 (pirtobrutinib).
The Pathology Department at Massachusetts General Hospital and Lunaphore, a Swiss life sciences company, entered a collaboration to develop an in vitro diagnostic that evaluates sensitivity of solid tumors to poly-ADP ribose polymerase inhibitors, with an initial focus on ovarian, breast, and prostate cancers.
The COVID-19 pandemic disrupted cancer screening and treatment and exacerbated health disparities, but also created unexpected opportunities in cancer research and care, a recent report from the American Association for Cancer Research states.
Ben Ho Park, Cornelius Abernathy Craig Professor of Medicine and deputy director of the Vanderbilt-Ingram Cancer Center, was named the center’s new director.
Ross Levine was named deputy physician-in-chief of translational research at Memorial Hospital, the main Manhattan hospital for Memorial Sloan Kettering Cancer Center.
The U.S, Senate Feb. 15 voted 50-46 to confirm Robert Califf as the next commissioner of FDA.
Arul M. Chinnaiyan, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences.
Roy S. Herbst was named the inaugural deputy director for clinical affairs at Yale Cancer Center and Smilow Cancer Hospital. The appointment is effective immediately and is in addition to Herbst’s role as chief of the Section of Medical Oncology and associate cancer center director for translational research at Yale Cancer Center.
Mark A. LemmonDaniel C. DiMaioMegan C. KingMark A. Lemmon, David A. Sackler Professor of Pharmacology, professor of molecular biophysics and biochemistry, and co-director of Yale’s Cancer Biology Institute, was appointed deputy director of Yale Cancer Center.
Candice Lucas was named the first chief community impact officer of the Wilmot Cancer Institute Community Outreach & Engagement, part of the University of Rochester.
